Showing 2121-2130 of 5771 results for "".
- Johnson & Johnson Vision Announces the US Launch of the Tecnis Multifocal Toric II IOLhttps://modernod.com/news/johnson-johnson-vision-announces-the-us-launch-of-the-tecnis-multifocal-toric-ii-iol/2477778/Johnson & Johnson Vision announced the US launch of the Tecnis Multifocal Toric II IOL, the first multifocal IOL approved on the new Tecnis Toric II platform. The square-edge Tecnis Multifocal Toric II implant features a new generation of frosted haptics, offering more surface texture and fri
- RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259https://modernod.com/news/regenerx-joint-venture-announces-efficacy-results-of-neurotrophic-keratopathy-phase-3-clinical-trial-with-rgn-259/2477764/ReGenTree LLC, a US joint venture company owned by GtreeBNT Co. and RegeneRx Biopharmaceuticals, announced the results of a randomized, double masked, placebo-controlled phase 3 clinical trial (SEER-1) using RGN-259 for the treatment of neurotrophic keratopathy (NK).
- ASRS Announces Virtual Annual Scientific Meeting July 24-26, 2020https://modernod.com/news/asrs-announces-virtual-annual-scientific-meeting-july-24-26-2020/2477759/Due to the COVID-19 pandemic, the American Society of Retina Specialists (ASRS) has decided to hold its annual meeting online. In a letter to membership, Timothy Murray, MD, MBA, ASRS President, and Philip Ferrone, MD, Program Chair, said that the ASRS Board of Directors has concluded that
- Ocular Therapeutix Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI For Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-1-clinical-trial-of-otx-csi-for-treatment-of-dry-eye-disease/2477754/Ocular Therapeutix announced that it has dosed the first patients in its phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). “We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease,” Michael Goldst
- Oyster Point Announces Results of Phase 3 Trial of OC-01 Nasal Spray for Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-results-of-phase-3-trial-of-oc-01-nasal-spray-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2477743/Oyster Point Pharma announced positive topline results from the phase 3 ONSET-2 study in dry eye disease. The ONSET-2 trial met the primary endpoint, where a greater percentage of subjects treate
- EyeXam and GenieMD Announce Mobile Collaboration in Eye Carehttps://modernod.com/news/eyexam-and-geniemd-announce-mobile-collaboration-in-eye-care/2477719/Mobile app EyeXam and GenieMD, a global provider of telemedicine solutions, announced a joint venture to introduce eyeXamVirtual, a telemedicine mobile solution. Together, GenieMD and EyeXam’s resources will enable consumers easy access to eye care providers physically and virtually,
- SightGlass Vision Announces R&D Webinar Featuring Leading Myopia Expertshttps://modernod.com/news/sightglass-vision-announces-rd-webinar-featuring-leading-myopia-experts/2477704/SightGlass Vision announced it will hold an R&D webinar to discuss the science of and latest research in myopia, as well as provide an overview about the clinical development and commercialization program for the company’s novel glasses designed to slow the progression of myopia in chil
- Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of Dextenza for Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-topline-results-of-phase-3-clinical-trial-of-dextenza-for-allergic-conjunctivitis/2477659/Ocular Therapeutix announced topline results from its phase 3 clinical trial to evaluate the safety and efficacy of Dextenza for the treatment of ocular itching associated with allergic conjunctivitis (AC). In the phase 3 trial, Dextenza met all prespecified primary endpoints as demonstrated by a
- New Dates Announced for BMC Virtual Spring Symposiumhttps://modernod.com/news/new-dates-announced-for-bmc-virtual-spring-symposium/2477658/Bryn Mawr Communications (BMC) has announced that its first virtual educational initiative, the BMC Virtual Spring Symposium, will now be held on May 29-30. The BMC Virtual Spring Symposium is designed to enable discussion, engagement, and live Q&A for members of the vision community w
- National Vision Announces Plans For the Gradual Reopening of Retail Locations to the Publichttps://modernod.com/news/national-vision-announces-plans-for-the-gradual-reopening-of-retail-locations-to-the-public/2477644/National Vision Holdings announced plans for the gradual reopening of retail locations to the public with enhanced safety protocols and a focus on meeting the essential, urgent and emergency eye health needs of patients and customers, according to a company news release. Beginning April 27